We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is Adlai Nortye Ltd. Sponsored ADR (ANL) Stock Outpacing Its Medical Peers This Year?
Read MoreHide Full Article
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Is Adlai Nortye Ltd. Sponsored ADR (ANL - Free Report) one of those stocks right now? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Adlai Nortye Ltd. Sponsored ADR is a member of the Medical sector. This group includes 1051 individual stocks and currently holds a Zacks Sector Rank of #3. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. Adlai Nortye Ltd. Sponsored ADR is currently sporting a Zacks Rank of #2 (Buy).
Over the past three months, the Zacks Consensus Estimate for ANL's full-year earnings has moved 3.6% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
Based on the latest available data, ANL has gained about 50.7% so far this year. At the same time, Medical stocks have gained an average of 1.2%. As we can see, Adlai Nortye Ltd. Sponsored ADR is performing better than its sector in the calendar year.
One other Medical stock that has outperformed the sector so far this year is Elevance Health (ELV - Free Report) . The stock is up 13.2% year-to-date.
In Elevance Health's case, the consensus EPS estimate for the current year increased 0.2% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Adlai Nortye Ltd. Sponsored ADR belongs to the Medical - Biomedical and Genetics industry, a group that includes 506 individual stocks and currently sits at #69 in the Zacks Industry Rank. This group has lost an average of 7.9% so far this year, so ANL is performing better in this area.
Elevance Health, however, belongs to the Medical Services industry. Currently, this 59-stock industry is ranked #80. The industry has moved +5% so far this year.
Investors with an interest in Medical stocks should continue to track Adlai Nortye Ltd. Sponsored ADR and Elevance Health. These stocks will be looking to continue their solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Is Adlai Nortye Ltd. Sponsored ADR (ANL) Stock Outpacing Its Medical Peers This Year?
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Is Adlai Nortye Ltd. Sponsored ADR (ANL - Free Report) one of those stocks right now? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Adlai Nortye Ltd. Sponsored ADR is a member of the Medical sector. This group includes 1051 individual stocks and currently holds a Zacks Sector Rank of #3. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. Adlai Nortye Ltd. Sponsored ADR is currently sporting a Zacks Rank of #2 (Buy).
Over the past three months, the Zacks Consensus Estimate for ANL's full-year earnings has moved 3.6% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
Based on the latest available data, ANL has gained about 50.7% so far this year. At the same time, Medical stocks have gained an average of 1.2%. As we can see, Adlai Nortye Ltd. Sponsored ADR is performing better than its sector in the calendar year.
One other Medical stock that has outperformed the sector so far this year is Elevance Health (ELV - Free Report) . The stock is up 13.2% year-to-date.
In Elevance Health's case, the consensus EPS estimate for the current year increased 0.2% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Adlai Nortye Ltd. Sponsored ADR belongs to the Medical - Biomedical and Genetics industry, a group that includes 506 individual stocks and currently sits at #69 in the Zacks Industry Rank. This group has lost an average of 7.9% so far this year, so ANL is performing better in this area.
Elevance Health, however, belongs to the Medical Services industry. Currently, this 59-stock industry is ranked #80. The industry has moved +5% so far this year.
Investors with an interest in Medical stocks should continue to track Adlai Nortye Ltd. Sponsored ADR and Elevance Health. These stocks will be looking to continue their solid performance.